Status:
COMPLETED
Study Evaluating AGG-523 in Subjects With Severe Osteoarthritis Requiring Total Knee Replacement
Lead Sponsor:
Wyeth is now a wholly owned subsidiary of Pfizer
Conditions:
Osteoarthritis
Eligibility:
All Genders
55+ years
Phase:
PHASE1
Brief Summary
The main purpose of the study is to find out if, after 4 weeks of dosing, signs of the investigational drug AGG-523, or its effects, can be measured in urine, blood, or the knee joint. A secondary pur...
Detailed Description
This is a multicenter study of 2 dosing regimens of AGG-523, an investigational aggrecanase inhibitor that is taken orally. Potential study subjects are those with severe Osteoarthritis (OA) of the kn...
Eligibility Criteria
Inclusion
- Generally healthy, men or women, at least 55 years old
- Osteoarthritis of the knee requiring total knee replacement surgery
Exclusion
- Other types of arthritis, like rheumatoid arthritis
- Recent major surgery (in past 3 months)
- Recent knee injections (in past 6 months)
Key Trial Info
Start Date :
May 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2008
Estimated Enrollment :
2 Patients enrolled
Trial Details
Trial ID
NCT00454298
Start Date
May 1 2007
End Date
March 1 2008
Last Update
July 29 2009
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Boston, Massachusetts, United States, 02120
2
Boston, Massachusetts, United States, 02215
3
Newton, Massachusetts, United States, 02462
4
Winchester, Massachusetts, United States, 01801